DI BELLA METHOD
>
DOCUMENTATION INDEX > MDB - Documents
Terminal differentiation of human promyelocytic leukaemia cells, HL-60, during the G1 period.
(22/05/2003)
Detail
Vitamin D receptor genotype and breast cancer in Latinas (United States).
(22/05/2003)
Detail
Will analogs of 1,25-dihydroxyvitamin D(3) (calcitriol) open a new era in cancer therapy?
(22/05/2003)
Detail
Vitamin D analogs in cutaneous malignancies.
(22/05/2003)
Detail
Human leukemic (HMC-1) mast cells are responsive to 1alpha, 25-dihydroxyvitamin D(3): selective promotion of ICAM-3 expression and constitutive presence of vitamin D(3) receptor.
(22/05/2003)
Detail
24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
(22/05/2003)
Detail
25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis.
(22/05/2003)
Detail
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
(22/05/2003)
Detail
1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck.
(22/05/2003)
Detail
1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.
(22/05/2003)
Detail
Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1.
(22/05/2003)
Detail
The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.
(22/05/2003)
Detail
Parathyroid hormone may be a cancer promoter - an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D.
(22/05/2003)
Detail
Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma.
(22/05/2003)
Detail
Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling.
(22/05/2003)
Detail